Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch

Overview

• Glucose biosensing firm's preliminary Q4 revenue rises 13%, beating analyst expectations

• Fiscal 2025 revenue grows 16% yr/yr, driven by sensor technology launch

• Company anticipates 11-13% revenue growth in 2026, driven by sensor volume growth

Outlook

• Dexcom anticipates 2026 revenue of $5.16 - $5.25 bln, growth of 11-13% over 2025

• Company expects 2026 non-GAAP gross profit margin of 63-64%

• Dexcom forecasts 2026 non-GAAP operating margin of 22-23%

Result Drivers

• G7 SENSOR LAUNCH - Dexcom's Q4 revenue growth driven by the launch of G7 15 Day sensor technology, per CEO Jake Leach

• INTERNATIONAL EXPANSION - International revenue increased by 18% in Q4, reflecting strong global demand

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Dexcom Inc is $84.71, about 25.7% above its January 9 closing price of $67.40

• The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nBw9Sg5fsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)